<DOC>
	<DOCNO>NCT00268788</DOCNO>
	<brief_summary>The purpose study evaluate effect subcutaneous administration immunoglobulin compare intravenous treatment , multifocal motor neuropathy NB . ONLY RECRUITING FROM DENMARK</brief_summary>
	<brief_title>Subcutaneous Immunoglobulin Treatment Multifocal Motor Neuropathy</brief_title>
	<detailed_description>Introduction Intravenous immunoglobulin ( IVIG ) treatment establish treatment modality Multifocal Motor Neuropathy ( MMN ) . In order maintain neuromuscular performance patient require lifelong treatment . Hospital-based treatment high cost inconvenience patient , particularly chronic disorder . Immunoglobulin preparation available subcutaneous use IgG replacement therapy . The safety efficacy subcutaneous infusion report comparable i.v . preparation , apply successfully autoimmune disorder . However patient MMN previously treat subcutaneous immunoglobulin . Hypothesis : Subcutaneous immunoglobulin treatment efficacious safe less patient inconvenience . Primary endpoint : Isokinetic muscle strength end treatment A v B ( subcutaneous v i.v . ) Secondary endpoint : Medical research council score ( MRC-score ) , 9-hole peg test , 10m walking , Nerve conduction parameter , SF-36 .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Neuritis</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Clinical diagnosis multifocal motor neuropathy , support electrophysiological finding Other severe medical condition Pregnancy lactation Anticoagulation therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>multifocal motor neuropathy</keyword>
	<keyword>subcutaneous</keyword>
	<keyword>IVIG</keyword>
	<keyword>gammaglobulin</keyword>
</DOC>